… A nonavalent human papillomavirus (HPV) vaccine has been licensed for use in women
and men up to age 45 years in the United States. The cost-effectiveness of HPV vaccination for …

… Studies have shown that the vaccine prevents cancer and saves money … vaccine for use
in women and men up to age 45, and this article estimates the cost-effectiveness of the vaccine …

… In addition, this study aims to examine the cost-effectiveness of the 9-valent vaccine when
boys … evidence of general trends on the ongoing cost-effectiveness evaluation of HPV vaccine. …

… papillomavirus (HPV) vaccines have been proven effective against cervical cancer. However,
HPV vaccination … assess the cost-effectiveness of incorporating different HPV vaccines into …

… HPV vaccine was released in 2019. However, collective evidence on cost-effectiveness of
HPV vaccination … We summarised evidence on the cost-effectiveness of HPV vaccine in China. …

… papillomavirus (HPV) vaccination … cost-effectiveness of four different HPV vaccine
products—Cervarix™, Cecolin®, GARDASIL®, and GARDASIL®9—for routine HPV vaccination of …

… schedules will provide similar protection and be cost-effective compared to … vaccination, (2)
a one-dose HPV vaccination schedule in which we assume that one dose of the HPV vaccine …

… Cost-effectiveness studies help stakeholders with decisions regarding human papillomavirus
(HPV) vaccination … the results of cost-effectiveness studies of HPV vaccination in girls, to …

… The CEAC shows the probability of the vaccination being cost effective with the current …
of HPV vaccination boys for being cost effective. At €20,000 this likelihood is 94% (Fig. 4). …

… to which cost-effectiveness at different CETs influenced HPV vaccine introduction decisions
… cost-effectiveness of introducing HPV vaccination for 12-year-old girls with country vaccine …